[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-329228-105":59,"doc-detail-329228-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","is-there-a-role-for-fapi-pet-in-urological-cancers","Is There a Role for FAPI PET in Urological Cancers?","","This work investigates the clinical utility of fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) in urological neoplasms, including prostate cancer, urothelial carcinoma, and renal cell carcinoma. Available evidence remains preliminary, yet FAPI PET shows potential for detecting primary prostate cancer with low PSMA expression, whereas PSMA PET/CT outperforms FAPI PET/CT for biochemical recurrence. In urothelial carcinoma, FAPI PET/CT improves detection over deoxy-2-[18F]fluoro-d-glucose PET/CT, especially for small lymph node metastases. Limited data exist for renal cell carcinoma, and further research is needed for theranostic and treatment-guiding roles.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/is-there-a-role-for-fapi-pet-in-urological-cancers/329228/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/is-there-a-role-for-fapi-pet-in-urological-cancers/329228.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What cancers are covered when assessing FAPI PET/CT?","Question",{"text":113,"@type":114},"The assessment includes prostate cancer, urothelial carcinoma, and renal cell carcinoma, using FAPI PET/CT as the main imaging approach.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does FAPI PET/CT perform in prostate cancer compared with PSMA PET/CT?",{"text":118,"@type":114},"FAPI PET/CT shows promise for detecting primary lesions with low PSMA expression, while PSMA PET/CT outperforms FAPI PET/CT for biochemical recurrence.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is FAPI PET/CT potentially valuable in urothelial carcinoma?",{"text":122,"@type":114},"FAPI PET/CT demonstrates higher detection rates than deoxy-2-[18F]fluoro-d-glucose PET/CT, particularly for small lymph node metastases that are often missed at primary staging.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},329228,1790650283,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Molecular Diagnosis & Therapy (2024) 28:721–725 [https://doi.org/10.1007/s40291-024-00735-9](https://doi.org/10.1007/s40291-024-00735-9)  \nIs There a Role for FAPI PET in Urological Cancers?  \nNaima Ortolan1,2 · Luca Urso1,2 · Ilaria Zamberlan1,2 · Luca Filippi3 · Nicolò Maria Buffi4 · Corrado Cittanti1,2 · Licia Uccelli1,2 · Mirco Bartolomei2 · Laura Evangelista5,6  \nAccepted: 26 July 2024 / Published online: 24 August 2024 © The Author(s) 2024  \nAbstract  \nThis work aims to investigate the utility of positron emission tomography/computed tomography (PET/CT) with fibroblast activation protein inhibitors (FAPI) in urological neoplasms, including prostate cancer, urothelial carcinoma, and renal cell carcinoma. Although the available data are very preliminary, FAPI PET showed potential for detecting primary prostate cancer with low prostate-specific membrane antigen expression, while prostate-specific membrane antigen PET/CT outperformed FAPI PET/CT in detecting biochemical recurrence. In urothelial carcinoma, FAPI PET/CT demonstrated increased detection rates compared with deoxy-2-[18F]fluoro-d-glucose PET/CT, in particular in small lymph node metastases, whose identification is still an unmet clinical need. Limited data are available for renal cell carcinoma. In conclusion, FAPI PET emerges as a promising imaging modality for urological neoplasms, in particular bladder cancer. Further research is warranted to establish its role in guiding therapeutic decisions and as a potential novel theranostic agent.  \nKey Points  \nAlthough the evidence from the literature is very preliminary, fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET) looks promising in urological cancers. FAPI deserves further investigation as a theranostic agent (labeled with 68Ga for imaging and 177Lu for radioligand therapy) in patients affected by urological cancers.  \nIn bladder cancer, FAPI PET seems to enable the detection of metastatic lesions unrevealed at contrastenhanced computed tomography and deoxy-2-[18F] fluoro-D-glucose PET, in particular small lymph nodes that are frequently missed at primary staging.  \nLess evidence in the literature is available in prostate cancer, with a conceivable synergic role to prostate-specific membrane antigen PET in the detection of primary tumors, and in renal cell carcinoma.  \n* Luca Urso[rsulcu@unife.it](rsulcu@unife.it)  \n1 Department of Translational Medicine, University of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy  \n2 Nuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, Ferarra, Italy  \n3 Nuclear Medicine Unit, Department of Oncohematology, Fondazione PTV Policlinico Tor Vergata University Hospital, Rome, Italy  \n1 Introduction  \nThe tumor microenvironment has emerged as a significant factor in cancer research, playing a crucial role in immune evasion and cancer progression [1] . The tumor microenvironment is a dynamic field and includes various cellular and non-cellular elements. Notably, cancerassociated fibroblasts represent a predominant component in many neoplasms. Cancer-associated fibroblasts are activated in response to inflammation and tissue damage and foster tumor growth alongside cancer cells [2] . Of particular interest, fibroblast activation protein (FAP), atransmembrane serine protease typically expressed at low levels or undetectable in healthy tissues, is overexpressed by cancer-associated fibroblasts and, consequently, significantly upregulated in most cancers (i.e . , colorectal, pancreatic, breast, and head and neck cancers and highgrade gliomas), presenting a potential target for theranostic approaches [2, 3] . In this paper, we provide an overview  \n4 Department of Urology, IRCCS-Humanitas Research Hospital, Milan, Italy  \n5 Department of Biomedical Science, Humanitas University, Pieve Emanuele, Italy  \n6 Nuclear Medicine Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy  \nof the current literature data regarding positron","cbCaimIAqKFxKkXX","https://ap.wps.com/l/cbCaimIAqKFxKkXX","pdf",713834,"English","# Abstract\n## Key Points\n## Introduction\n## [68Ga]Ga-FAPI PET in Prostate Cancer","[{\"question\":\"What cancers are covered when assessing FAPI PET/CT?\",\"answer\":\"The assessment includes prostate cancer, urothelial carcinoma, and renal cell carcinoma, using FAPI PET/CT as the main imaging approach.\"},{\"question\":\"How does FAPI PET/CT perform in prostate cancer compared with PSMA PET/CT?\",\"answer\":\"FAPI PET/CT shows promise for detecting primary lesions with low PSMA expression, while PSMA PET/CT outperforms FAPI PET/CT for biochemical recurrence.\"},{\"question\":\"Why is FAPI PET/CT potentially valuable in urothelial carcinoma?\",\"answer\":\"FAPI PET/CT demonstrates higher detection rates than deoxy-2-[18F]fluoro-d-glucose PET/CT, particularly for small lymph node metastases that are often missed at primary staging.\"}]","Is There a Role for FAPI PET in Urological Cancers? | PDF",1789983168,13]